TCN 201 selectively blocks GluN2A-containing NMDARs in a GluN1 co-agonist dependent but non-competitive manner  by Edman, S. et al.
at SciVerse ScienceDirect
Neuropharmacology 63 (2012) 441e449Contents lists availableNeuropharmacology
journal homepage: www.elsevier .com/locate/neuropharmTCN 201 selectively blocks GluN2A-containing NMDARs in a GluN1 co-agonist
dependent but non-competitive manner
S. Edman a,b, S. McKay a, L.J. MacDonald a, M. Samadi a, M.R. Livesey a, G.E. Hardingham a, D.J.A. Wyllie a,*
aCentre for Integrative Physiology, University of Edinburgh, Hugh Robson Building, George Square, Edinburgh EH8 9XD, UK
b Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, SE 405 30 Gothenburg, Swedena r t i c l e i n f o
Article history:
Received 9 February 2012
Received in revised form
19 April 2012
Accepted 23 April 2012
Keywords:
TCN 201
TCN 213
NMDA receptor
GluN2A-selective
Glycine
D-serine
Schild analysis* Corresponding author. Tel.: þ44 131 650 4564; fa
E-mail address: dwyllie1@staffmail.ed.ac.uk (D.J.A
0028-3908/ 2012 Elsevier Ltd.
doi:10.1016/j.neuropharm.2012.04.027
Open access under CC BYa b s t r a c t
Antagonists that are sufﬁciently selective to preferentially block GluN2A-containing N-methyl-D-aspar-
tate receptors (NMDARs) over GluN2B-containing NMDARs are few in number. In this study we describe
a pharmacological characterization of 3-chloro-4-ﬂuoro-N-[4-[[2-(phenylcarbonyl)hydrazino]carbonyl]
benzyl]benzenesulphonamide (TCN 201), a sulphonamide derivative, that was recently identiﬁed from
a high-throughput screen as a potential GluN2A-selective antagonist. Using two-electrode voltage-clamp
(TEVC) recordings of NMDAR currents from Xenopus laevis oocytes expressing either GluN1/GluN2A or
GluN1/GluN2B NMDARs we demonstrate the selective antagonism by TCN 201 of GluN2A-containing
NMDARs. The degree of inhibition produced by TCN 201 is dependent on the concentration of the
GluN1-site co-agonist, glycine (or D-serine), and is independent of the glutamate concentration. This
GluN1 agonist-dependency is similar to that observed for a related GluN2A-selective antagonist, N-
(cyclohexylmethyl)-2-[{5-[(phenylmethyl)amino]-1,3,4-thiadiazol-2-yl}thio]acetamide (TCN 213). Schild
analysis of TCN 201 antagonism indicates that it acts in a non-competitive manner but its equilibrium
constant at GluN1/GluN2A NMDARs indicates TCN 201 is around 30-times more potent than TCN 213. In
cortical neurones TCN 201 shows only modest antagonism of NMDAR-mediated currents recorded from
young (DIV 9e10) neurones where GluN2B expression predominates. In older cultures (DIV 15e18) or in
cultures where GluN2A subunits have been over-expressed TCN 201 gives a strong block that is nega-
tively correlated with the degree of block produced by the GluN2B-selective antagonist, ifenprodil.
Nevertheless, while TCN 201 is a potent antagonist it must be borne in mind that its ability to block
GluN2A-containing NMDARs is dependent on the GluN1-agonist concentration and is limited by its low
solubility.
 2012 Elsevier Ltd. Open access under CC BY license.1. Introduction
NMDARs are a subtype of the ionotropic glutamate receptor
family and are tetrameric assemblies, the majority of which contain
two GluN1 subunits and two GluN2 subunits (Collingridge et al.,
2009; Traynelis et al., 2010). It is thought that these subunits
assemble in a ‘dimer of dimers’ conﬁguration (Schorge and
Colquhoun, 2003) forming a central non-selective cation-con-
ducting ion channel pore that is permeable to Naþ, Kþ and Ca2þ ions
but which is blocked by Mg2þ ions in a voltage-dependent manner
(Traynelis et al., 2010). Alternative splicing of exons 5, 21 and 22
gives rise to eight GluN1 subunit isoforms (Sugihara et al., 1992)
while 4 separate genes encode GluN2A-D subunits. These GluN2
subunits are spatially and temporally regulated (Monyer et al., 1994,x: þ44 131 650 2872.
. Wyllie).
 license.1992) and give rise to the majority of the distinct pharmacological
and biophysical properties exhibited by NMDAR subtypes (Chen
and Wyllie, 2006; Erreger et al., 2004; Traynelis et al., 2010).
In vivo glutamate binds to the ligand-binding domain (LBD) of
GluN2 subunits, while glycine (or D-serine) binds to the homolo-
gous structure in GluN1 subunits and activation of NMDARs has an
absolute requirement that these sites are occupied by their
respective ligands (Johnson and Ascher, 1987; Kleckner and
Dingledine, 1988). Conversely, antagonism of NMDARs can be
achieved by blocking agonist function at either GluN1 or GluN2
LBDs.
Relatively few NMDAR subtype-selective antagonists exist
(Ogden and Traynelis, 2011) and until recently only the non-
competitive allosteric inhibitors ifenprodil (Williams, 1993), CP
101,606 (Mott et al., 1998) and Ro 256981 (Fischer et al., 1997) are
sufﬁciently selective for GluN2B-containing NMDARs to be identi-
ﬁed unambiguously. For GluN2A-containing NMDARs the
competitive antagonist NVP-AAM077 (Auberson et al., 2002) can be
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but care must be taken to use this antagonist at concentration that
has minimal action at GluN2B-containing NMDARs since it only
weakly discriminates between these two NMDAR subtypes (Frizelle
et al., 2006; Neyton and Paoletti, 2006; Wyllie and Chen, 2007).
More promisingly, two compounds have recently been identi-
ﬁed (Bettini et al., 2010), now referred to as TCN 201 (originally
called Compound 1) and TCN 213 (originally Compound 13), that
appear to be selective for GluN1/GluN2A over GluN1/GluN2B
NMDARs. In a recent study we have characterized the nature of TCN
213 antagonism and have demonstrated that this compound
displays a high selectivity for GluN2A-containing NMDARs and can
be used to monitor, pharmacologically, the switch in NMDAR
expression in developing cortical neurones (McKay et al., 2012). The
mechanism of TCN 213 appears to be paradoxical in nature; whilst
the compound selects for GluN2A-containing NMDARs, the potency
of TCN 213 block is dependent on the concentration of glycine and
not that of glutamate. Using Schild analysis, TCN 213 was found to
possess an equilibrium constant (KB) of 2 mM. Although estimates of
the concentration of glycine (or D-serine) in vivo have not been
determined, unequivocally, they are likely to be in the micromolar
range, while typically concentrations of at least 30 mM are con-
tained in artiﬁcial cerebro-spinal ﬂuid solutions when performing
assays of NMDAR function to ensure saturation of the GluN1
binding site. Use of glycine (or D-serine) at this concentration,
which is equal to 20  its EC50 value at GluN1/GluN2A NMDARs
(Chen et al., 2008), limits the effectiveness of TCN 213 due to this
antagonist’s comparatively low afﬁnity. Therefore relatively high
concentrations of TCN 213 need to be used to achieve substantial
block of GluN2A NMDAR-mediated responses (McKay et al., 2012).
The present study reports the pharmacological characterization
of TCN 201 e an antagonist suggested to be more potent than TCN
213 (Bettini et al., 2010) while still discriminating between GluN1/
GluN2A and GluN1/GluN2B NMDARs. Our data show that TCN 201
is indeed more potent than TCN 213, but like TCN 213, its antago-
nism is also GluN1 co-agonist dependent. Furthermore the nature
of its antagonism is not competitive and our results are consistent
with it having an allosteric modulatory effect on glycine (or D-
serine) binding. Complementary to our recent genetic approach to
elucidate the GluN2 subunit dependency of NMDAR excitotoxicity
(Martel et al., 2012), TCN 201 can also be used to assess the
contribution of GluN2A subunits and adds to the list of new
GluN2A-selective ligands in the pharmacological toolbox that can
be used to elucidate NMDAR subunit composition and function.
2. Materials and methods
2.1. Plasmid constructs, cRNA synthesis and receptor expression in oocytes
Nomenclature of NMDA receptor subunits follows Collingridge et al. (2009) and
Alexander et al. (2011). pSP64T-based plasmid constructs containing cDNA coding
for rat GluN1-1a (i.e. the splice variant that lacks exon 5, but contains exons 21 and
22), hereafter termed GluN1 and wild-type rat GluN2A receptor subunits were
prepared as described by (Chen et al., 2005). The rat GluN2B-containing cDNA
expression vector was a gift by Stephen Traynelis (Emory University, Atlanta, GA).
cRNAwas synthesized as runoff transcripts as previously detailed (Chen et al., 2005,
2008; Erreger et al., 2007). Fluorescence intensity in ethidium bromide-stained
agarose gels was employed to conﬁrm the ﬁdelity and yield of synthesized cRNAs.
For recombinant receptor expression, GluN1 and GluN2 cRNAs were mixed at
a nominal ratio of 1:1 and diluted with nuclease-free water to 5 ng ml1.
Oocytes (Stage VeVI) were removed from Xenopus laevis that had been killed in
accordance with current UK Home Ofﬁce protocols and defolliculated by initial
collagenase treatment, then manually using forceps. 23e37 nl of cRNA mix was
injected into oocytes which were subsequently maintained in Barth’s solution
(composition in mM: NaCl 88, KCl 1, NaHCO3 2.4, MgCl2 0.82, CaCl2 0.77, Tris-Cl
15, adjusted to pH 7.35 with NaOH and supplemented with 50 IU ml1 penicillin,
50 mg ml1 streptomycin, 50 mg ml1 tetracycline) for 24e48 h at 19 C to allow for
receptor expression and then stored at 4 C until required for electrophysiological
measurements.2.2. Culture of rat cortical neurones
Cortical neurones from E21 SpragueeDawley rat embryos were cultured as
described previously (Bading and Greenberg,1991;Martel et al., 2009; Papadia et al.,
2008) except that the Neurobasal-A growth medium contained B27 (Invitrogen,
Paisley, UK), 1% rat serum (Harlan UK Ltd, Oxon, UK) and 1 mM glutamine. At days
in vitro (DIV) 4, 1 ml growth medium containing 9.6 mM cytosine b-D-arabinofur-
anoside hydrochloride (AraC) was added to each well to inhibit glial cell prolifera-
tion. Culture media were replenished every 2 days after DIV 9 by replacing 1 ml of
the conditioned media with 1 ml of fresh growth medium that lacked rat serum but
was supplemented with glucose (10 mM).
2.3. Transfection of cortical neurones
Neurones were transfected on DIV 7 using Lipofectamine 2000 (Invitrogen)
according to the manufacturer’s suggested protocol. Brieﬂy, pCis-GluN2A (0.4 mg)
(Rutter and Stephenson, 2000) together with eGFP (0.2 mg) in a volume of 333 ml was
added per well of a 24-well plate. After 5 h this transfection solution was removed
and replaced with Neurobasal-A growth medium (2 ml per well). Transfected
neurones were incubated to enable GluN2A expression for a further 2e3 days (DIV
9e10). We have previously demonstrated that co-transfection of b-globin and eGFP
did not signiﬁcantly alter ifenprodil sensitivity of DIV 7e11 neurones (McKay et al.,
2012) and in the present study non-transfected DIV 9e10 cells were used as
‘controls’ in sister cultures. Transfection efﬁciency was approximately 5% with>99%
of eGFP-expressing cells being identiﬁed as NeuN-positive while <1% were GFAP
positive (Soriano et al., 2008). Electrophysiological recordings were made from
transfected neurones 48e72 h post-transfection.
2.4. Electrophysiological recordings
Two-electrode voltage-clamp (TEVC) recordings were made using a GeneClamp
500 ampliﬁer (Molecular Devices, Sunnyvale, CA) at room temperature (18e21 C)
from oocytes placed in a bath that was perfused with a solution comprising (in
mM): NaCl 115, KCl 2.5, HEPES 10, BaCl2 1.8, EDTA 0.01; pH 7.4with NaOH. Note EDTA
was included to chelate contaminating low nanomolar levels of Zn2þ that potently
block of GluN2A-containing NMDARs in a voltage-independent manner. Current and
voltage electrodes were made from thin-walled borosilicate glass (GC150TF-7.5,
Harvard Apparatus, Kent, UK) using a PP-830 electrode puller (Narishige Instru-
ments, Tokyo, Japan) and when ﬁlled with 0.3 M KCl possessed resistances of
between 1 and 2 MU. TEVC recordings were performed at 30 or 40 mV. Currents
were ﬁltered at 10 Hz and digitized online at 100 Hz, via a Digidata 1200 A/D
interface (Molecular Devices, Union City, CA, USA), using WinEDR 3.1.9 software
(Strathclyde Electrophysiology Software, Strathclyde University, UK).
Whole-cell NMDA-evoked currents in rat cultured cortical neurones were
recorded using an Axopatch 200B ampliﬁer (Molecular Devices) using patch-
pipettes made from thick-walled borosilicate glass with a tip resistance of
4e8 MU that were ﬁlled with an ‘internal’ solution that contained (in mM): K-
gluconate 141, NaCl 2.5, HEPES 10, EGTA 11; pH 7.3 with KOH. Experiments were
conducted at room temperature (18e21 C) in an ‘external’ solution containing (in
mM): NaCl 150, KCl 2.8, HEPES 10, CaCl2 2, glucose 10, EDTA 0.01; pH to 7.3 with
NaOH. Picrotoxin (50 mM) and tetrodotoxin (300 nM) were included to block GABAA
receptor-mediated responses and action potential driven excitatory/inhibitory
postsynaptic events, respectively. Access resistances were monitored and recordings
where this changed by >20% were discarded. Currents were ﬁltered at 2 kHz and
digitized online at 5 kHz via a BNC-2090A/PCI-6251 DAQ board interface (National
Instruments, Austin, TX, USA) and analyzed using WinEDR 3.1.9 software (Dr John
Dempster, University of Strathclyde, Glasgow, UK).
2.5. Assessment of antagonist potencies
The concentration of TCN 201 required to inhibit 50% (IC50) of agonist-evoked
responses were determined by ﬁtting data to the equation:
I ¼ I½BN þ

I½B0  I½BN
.
1þ ð½B=IC50ÞnH

;
where I is current response, I½B0 is predicted maximum current in the absence of
antagonist, I½BN is the predicted minimum current in the presence of an inﬁnite
concentration of antagonist,[B] is the concentration of the antagonist and nH repre-
sents the Hill coefﬁcient. To obtain an overall mean IC50 value, data points were nor-
malised to the predicted maximum, pooled and reﬁtted with the equation, with the
maximum of each curve being constrained to asymptote to 1 but with the minimum
ﬁttedasa freeparameter (Ottonetal., 2011;Wrightonetal., 2008). Inadditionweﬁtted
data points where both the maximum and minimum were constrained (to 1 and 0,
respectively). The F ratio was calculated from the following equation:
F ¼ ðSSR1  SSR2Þ=ðDF1  DF2Þ
SSR2=DF2
;
where SSR1 and SSR2 are the sum of squared residuals of the constrained and
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ciated with each of the two ﬁts.
2.6. Schild analysis
TCN 201 antagonism at the GluN1/GluN2A NMDAR was examined by the Schild
method (Arunlakshana and Schild, 1959; Wyllie and Chen, 2007). Dose-ratios (r) were
deﬁned as the ratio of the concentration of agonist, in the presence of a ﬁxed concen-
tration of antagonist, required to evoke the same response that was obtained in the
absence of the antagonist. Dose-ratios from individual oocyteswere determined at low
agonist concentrations by constructing a partial concentration-response curve gener-
ated in the absenceof antagonist and in the presenceof a series of increasing antagonist
concentrations. Due to the lack of sufﬁcient perfusion lines, the dose-ratio estimate for
thehigher concentrations of TCN201 (3 and10 mM)wasdetermined in a separate series
of experiments from those carried out for the lower two concentrations (0.3 and 1 mM).
Each series of two-point concentration-response curveswereplottedona logelog scale
and the slopeof the lineused toﬁt the initial (antagonist-free) two-point concentration-
response curve was used to ﬁt the remaining curves. These parallel ﬁts were used to
calculate anoverallmean rvalue for eachantagonist concentration [B],whichwere then
used to construct a Schild plot.Ona logelog scale the gradient of the line used toﬁt such
data is predictedby the Schild equation to be unity for a competitive antagonist. Thus, if
the slope of a ‘free’ ﬁt was not signiﬁcantly different from1, then the resultswere taken
tobe consistentwith the Schild equation, and thedatawere reﬁttedwith the slopeﬁxed
at 1, i.e. they were reﬁtted with the Schild equation,
r  1 ¼ ½B
KB
;
in which the only free parameter is the intercept on the x-axis and which gives the
equilibrium constant for antagonist binding, KB. For ‘allosteric’ antagonism at
equilibrium, the Schild plot deviates from unity at higher concentrations of antag-
onist (Christopoulos and Kenakin, 2002). Such data can be ﬁtted with the following
modiﬁed equation:
r  1 ¼ ½Bð1 aÞ
a½B þ K#B
;
where a is the allosteric constant and KB# is the estimated allosteric antagonist
dissociation constant. Note that if a ¼ 0, this equation simply reduces to the Schild
equation. In addition, and unlike the Schild equation, KB# does not give an r value equal
to 2 when KB# equals [B] but rather will give an r value < 2 for 0 < a < 1 and thus KB#
should not be interpreted in the same way as the KB of a competitive antagonist.
2.7. Chemicals
Glutamate, glycine and D-serine were purchased from SigmaeAldrich (Poole, UK).
TCN 201, TCN 213, NMDA, ifenprodil, picrotoxin and tetrodotoxin were purchased
from Tocris Bioscience (Bristol, UK). Stock solutions (3 mM) of TCN 201 were made by
dissolving the antagonist in DMSO. Due to the limited solubility of TCN 201 the
maximum concentration used in our experiments was 10 mM e at higher concen-
trations a noticeable precipitatewas observed in the external recording solutions used
in either the TEVC experiments or whole-cell patch-clamp experiments.
2.8. Statistical analysis
Results are presented as mean  standard error of the mean and statistical
comparison between datasets was assessed using either Student’s t-test (paired
where appropriate) or analysis of variance (ANOVA) tests to determine whether
differences between mean values were signiﬁcant (p < 0.05). Analysis of the ﬁtting
inhibition curves to unconstrained or constrained minima was assessed using an F-
test. Microcal Origin v8.0 software was used for graphical presentation.
3. Results
3.1. TCN 201 demonstrates potent but GluN1 co-agonist
concentration-dependent inhibition of GluN1/GluN2A NMDAR-
mediated responses
Fig. 1ai shows two representative TEVC current traces recorded
from a X. laevis oocyte and mediated by recombinantly expressed
GluN1/GluN2A NMDARs. The extent of the antagonism exhibited by
TCN 201 is dependent on the glycine concentration present in the
external recordingsolutionandnoticeably less inhibition ispresent in
the righthand trace ([glycine] ¼ 30 mM; 20  its EC50 value). Fig. 1aii
illustrates a comparable experiment where TCN 213, rather thanTCN
201, was used e again note the decrease in the level of inhibitionwhen glycine is present at the higher concentration. Fig. 1aiii shows
themean inhibition observed in a series of experiments for both TCN
201 and TCN 213 antagonism of GluN1/GluN2A NMDAR-mediated
currents recorded in the presence of the lower (10 mM) or higher
(30 mM) external glycine concentration. On average, andwith glycine
at 10 mM, TCN 201 produced 82.4  1.1% (n ¼ 12) inhibition whereas
TCN 213 gave signiﬁcantly less block (44.0  2.2%; n ¼ 11) of GluN1/
GluN2A NMDAR-mediated currents (p < 0.001). Although both TCN
201 and TCN 213 gave less inhibition of currents evoked in the
presence of the higher glycine concentration (50.7  1.1%; n ¼ 8 and
17.31.4%;n¼ 9, respectively) the difference inpotency between the
two antagonists is still clearly evident (p < 0.001).
In contrast to the observed glycine dependency, the potency of
block of TCN 201 (10 mM) was not dependent on the glutamate
concentration used to evoke GluN1/GluN2A NMDAR-mediated
currents (Fig. 1b). In these experiments glutamate was applied at
either 3, 10 or 30 mM, while the glycine concentration was ﬁxed at
30 mM. For each of the glutamate concentrations tested, the extent
of block by TCN 201 was not signiﬁcantly different (F(2,14) ¼ 1.839,
p ¼ 0.19, one-way ANOVA), with the mean values for the
percentage inhibition being 54.5  3.4% (n ¼ 5; 3 mM), 52.2  3.7%
(n ¼ 6; 10 mM) and 45.8  2.8% (n ¼ 6; 30 mM).
To assess TCN 201’s selectivity for GluN1/GluN2A NMDARs
a similar series of experiments to those illustrated in Fig. 1ai were
performed but in oocytes that expressed GluN1/GluN2B NMDARs.
As shown in Fig. 1c TCN 201 (10 mM) produced only slight inhibition
of GluN1/GluN2B NMDAR-mediated currents. For glycine concen-
trations of 3, 10 and 30 mM the extent of block by TCN 201 was not
signiﬁcantly different (F(2,15) ¼ 0.8116, p ¼ 0.46, one-way ANOVA),
with the mean values for the percentage inhibition being 1.8 0.6%
(n ¼ 6; 3 mM), 3.1  1.0% (n ¼ 6; 10 mM) and 3.1  0.8% (n ¼ 6;
30 mM). Thus our data demonstrate that TCN 201 selectively block
GluN1/GluN2A NMDARs but in a manner that is dependent on the
concentration of the GluN1-site agonist.
3.2. Inhibition curves for TCN 201 acting at GluN1/GluN2A NMDARs
activated by glutamate and glycine or D-serine
We quantiﬁed the potency of TCN 201 by determining its IC50
value at GluN1/GluN2A NMDARs under conditions where either
glycine or D-serinewas used as the GluN1-site agonist. Additionally,
since IC50 values are dependent on the concentration of the agonist
used to evoke responses (Wyllie and Chen, 2007) three concentra-
tions of each agonistwere examined. As glycine and D-serine display
the same potency at GluN1/GluN2A NMDARs (Chen et al., 2008) we
were able to use the same concentrations of each agonist in this
series of experiments. Fig. 2ai shows a representative TEVC current
trace where the NMDAR-mediated current was evoked by a satu-
rating concentration of glutamate (30 mM; (Erreger et al., 2007)) and
glycine (3 mM; 2  its EC50 value). Increasing concentrations
(0.03e10 mM) of TCN 201 were applied cumulatively to inhibit the
current. Fig. 2aii illustrates a similar experiment but under condi-
tionswhere theglycine concentrationwas increased (30mM;20 its
EC50 value). It is evident that TCN 201 causes substantially less
inhibition of the TEVC current trace illustrated in Fig. 2aii. Themean
data obtained froma series of such experiments are shown in Fig. 2b.
As described inMaterials andMethods these datawere ﬁtted in two
ways e either the predicted minimum value of the ﬁt was left
unconstrained (solid lines) or constrained to asymptote to zero
(dashed lines). For each of the glycine concentrations examined
ﬁtting the data points with curves with an unconstrained minima
led to signiﬁcantly improved theﬁts (F(4,3)¼10.34,p¼0.0422; 3mM;
F(4,3) ¼ 17.43, p ¼ 0.0204; 10 mM; F(4,3) ¼ 36.28, p ¼ 0.0071; 30 mM)
which leads to the prediction that TCN 201 will not completely
inhibit responses mediated by GluN1/GluN2A NMDARs. The
Fig. 1. TCN 201 antagonism of NMDAR-mediated responses is both subtype- and glycine-dependent and more potent than TCN 213. (ai), upper panel, molecular structure of TCN
201. Lower panel, TEVC currents recorded from an oocyte expressing GluN1/GluN2A NMDARs in response to application of glutamate (30 mM) and glycine (10 mM, left-hand
trace; 30 mM, righthand trace). TCN 201 (10 mM) was applied as indicated and inhibited the glutamate/glycine-evoked response but the extent of the inhibition was depen-
dent on the glycine concentration. (aii), upper panel, molecular structure of TCN 213. Lower panel, a series of similar TEVC current traces in equivalent conditions, but recorded in
the presence of TCN 213 (10 mM). (aiii), bar graphs summarizing the mean data obtained from a series of experiments that investigated the glycine-dependency of TCN 201
(10 mM, n ¼ 12; 30 mM, n ¼ 8) and TCN 213 (10 mM, n ¼ 11; 30 mM, n ¼ 9) antagonism of steady-state responses at GluN1/GluN2A NMDARs. (b), a series of representative TEVC
current traces illustrating similar experiments as in (a), but where the glycine concentration was ﬁxed (30 mM) and glutamate was applied at either 3, 10 or 30 mM. The bar graph
summarizes the mean data obtained from a series of experiments that investigated the glutamate-dependency of TCN 201 antagonism of steady-state responses at GluN1/
GluN2A and NMDARs at 3 mM (n ¼ 5), 10 mM (n ¼ 6) and 30 mM (n ¼ 6). (c), a series of representative TEVC current traces illustrating similar experiments to that shown in (a), but
for recordings made from oocytes expressing GluN1/GluN2B NMDARs. Note here the modest inhibition produced by TCN 201. The bar graph summarizes the mean data obtained
from a series of experiments that investigated the glycine-dependency of TCN 201 antagonism of steady-state responses at GluN1/GluN2B NMDARs at 3 mM (n ¼ 6), 10 mM (n ¼ 6)
and 30 mM (n ¼ 6).
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antagonist that gives 50% of the maximal amount of inhibition that
can be achieved) andHill slopeswere0.4460.026 mM,1.420.061
(n ¼ 15, [glycine] ¼ 3 mM), 0.746  0.133 mM, 1.49  0.21 (n ¼ 5,
[glycine] ¼ 10 mM) and 3.89  1.06 mM, 1.17  0.11 (n ¼ 10,
[glycine] ¼ 30 mM). We carried out a similar series of experiments
and analyses using D-serine as the GluN1-site agonist (Fig. 2c, d) and
again found that ﬁtting the datasets with curves where the minima
were left unconstrained produced signiﬁcantly betterﬁts than those
where the minima were constrained to asymptote to zero
(F(4,3) ¼ 106.95, p ¼ 0.0014; 3 mM; F(4,3) ¼ 18.74, p ¼ 0.0184; 10 mM;
F(4,3) ¼ 38.63, p ¼ 0.0065; 30 mM). The respective calculated IC50
values and Hill slopes obtained from these ﬁts were
0.326  0.018 mM, 1.57  0.078 (n ¼ 6, [D-serine] ¼ 3 mM),
0.816  0.231 mM, 1.33  0.21 (n ¼ 6, [D-serine] ¼ 10 mM) and
1.92  0.25 mM, 1.17  0.07 (n ¼ 6, [D-serine] ¼ 30 mM).Thus each of the datasets obtained at either the lower, inter-
mediate or higher GluN1-site agonist concentration were better
ﬁtted with curves in which their minima were unconstrained.
This indicates that TCN 201 will not produce complete block of
NMDAR-mediated responses and is consistent with the notion
that the antagonism is non-competitive in nature. Furthermore,
the mean values for TCN 201 inhibition of GluN1/GluN2A
NMDAR-mediated currents were signiﬁcantly different
(p ¼ 0.0119, two-tailed t-test) when D-serine, rather than glycine
was used as the GluN1-site agonist at the lowest concentration
examined (3 mM). This ‘agonist-dependency’ of IC50 values is not
unexpected given that IC50 values are dependent on agonist
afﬁnity and efﬁcacy. Thus, we therefore decided to investigate
further the nature of TCN 201’s antagonism by carrying out
Schild analysis which does not suffer from such limitations
(Wyllie and Chen, 2007).
Fig. 2. Inhibition curves for TCN 201 antagonism of GluN1/GluN2A NMDAR-mediated responses activated by co-agonists glycine or D-serine. (ai), TEVC trace recorded from an
oocyte expressing GluN1/GluN2A NMDARs and voltage-clamped at 30 mV. The upper bar in this trace and in panels (aii), (ci) and (cii) indicates the duration of the bath application
of glutamate/glycine, while the shaded bar in this panel (and in (ai), (ci) and (cii)) indicates the co-application TCN 201. Increasing concentrations of TCN 201 were applied,
cumulatively, as indicated by the arrowheads. (aii), as in (ai), but currents are evoked using a higher concentration of glycine (30 mM). Note that TCN 201-mediated inhibition is less
at this higher glycine concentration. (b), mean normalised inhibition curves for TCN 201 block of GluN1/GluN2A NMDAR-mediated currents evoked by glutamate (30 mM) and either
3 mM (n ¼ 15;-), 10 mM (n ¼ 5;
▲
) or 30 mM (n ¼ 10;
●
) glycine. The solid curves show the ﬁt with the minimum ﬁtted as a free parameter, whereas the dashed curves show the ﬁt
of the data points when the minimum valued was constrained to 0 (see Materials and methods). (ci), as in (ai) but where currents were evoked by glutamate (30 mM) and D-serine
(3 mM), again increasing concentrations of TCN 201 (0.03e10 mM) were applied, cumulatively, as indicated by the arrowheads. (cii), as in (ci), but where currents were the D-serine
was 30 mM. (d), mean normalised inhibition curves for TCN 201 block of GluN1/GluN2A NMDAR-mediated currents activated by glutamate (30 mM) and either 3 mM (n ¼ 6; -),
10 mM (n ¼ 6;
▲
) or 30 mM (n ¼ 6;
●
) D-serine.
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NMDAR-mediated currents
Schild analysis (Arunlakshana and Schild, 1959; Wyllie and
Chen, 2007) allows the unambiguous determination of the equi-
librium constant (KB) for a competitive antagonist and is inde-
pendent of the nature and concentration of agonist. Fig. 3a, b shows
TEVC current traces that exemplify experiments carried out to
determine the dose ratio (r) for shifts in glycine potency in the
presence of increasing (0.3e10 mM) concentrations of TCN 201.
Speciﬁcally, Fig. 3a depicts a series of recordings from a single
oocyte where two concentrations of glycine (in the presence of
glutamate (30 mM)) are applied in the absence (upper trace) or
presence (middle and lower traces) of TCN 201 (0.3 and 1 mM).
Fig. 3b shows a similar experiment but when the TCN 201
concentration was increased (3 and 10 mM). From these we con-
structed two-point concentration-response curves (Fig. 3c, d) and
estimated r for each concentration of antagonist (n¼ 7). Themean r
values obtained were 5.19  0.4, 16.7  2.1, 41.11.5 and 49.0  2.0
for 0.3, 1, 3 and 10 mM TCN 201, respectively. Note that the shift in
the concentration-response curve in the presence of the highestconcentration of TCN 201 (10 mM) is considerably less than would
be predicted for competitive antagonism. Indeed this smaller than
predicted shift is clearly observed in the Schild plot (Fig. 3e).
However the ﬁrst three data points (0.3, 1 and 3 mM TCN 201)
appear to give a straight line. A linear regression ﬁt of these data
gives a line with a slope of 0.98 (95% conﬁdence interval:
0.85e1.14). The ﬁt of the data (solid line) illustrated in Fig. 3e shows
a line whose slope has been constrained to unity and allows the
derivation of the KB for TCN 201 (70 nM). For comparison, data
obtained from our study of TCN 213 antagonism (McKay et al.,
2012) is illustrated e note the lower potency of this antagonist
(KB ¼ 2 mM). Clearly however, the entire dataset for TCN 201
antagonism is not satisfactorily described by the Schild equation
and this can be taken to indicate that TCN 201 is not acting in
a competitive manner at the GluN1 agonist binding site (as indeed
is also suggested by the data presented in Fig. 2). Thus, the dotted
line (Fig. 3e) shows the complete dataset ﬁtted with a modiﬁed
equation (Christopoulos and Kenakin, 2002) which has previously
been used to described agonist-surmountable ‘allosteric’ non-
competitive antagonism at G-protein coupled receptors. This ﬁt
better describes the data and gives an allosteric KB# of 56 nM and an
Fig. 3. Schild analysis of TCN 201 antagonism of GluN1/GluN2A NMDAR-mediated responses. (a), illustration of a set of TEVC current traces, obtained from an oocyte expressing
GluN1/GluN2A NMDARs, used to generate ‘two-point’ doseeresponse curves in either the absence or presence of TCN 201 (0.3 and 1 mM; n ¼ 7). (b), as in (a) but for higher TCN 201
concentrations (3 and 10 mM; n ¼ 7). (c) and (d), partial, low-concentration, doseeresponse curves obtained from the TEVC current traces illustrated in (a) and (b), respectively, and
used to estimate dose ratios (DR0.3, 1, 3, 10). The slope of the ﬁtted line to the control responses (no TCN 201;-) was used to ﬁt the responses obtained in the presence of 0.3 mM (●),
1 mM (
▲
), 3 mM (
▼
) and 10 mM (♦). (e), Schild plot for antagonism by TCN 201 of GluN1/GluN2A NMDARs using dose-ratios estimated from a series experiments such as that
illustrated in (c) and (d). A ‘free’ ﬁt of the 0.3, 1 and 3 mM TCN 201 data points gave has a slope of 0.98 which was considered not to be signiﬁcantly different from 1 (95% conﬁdence
interval: 0.85e1.14). Thus the solid line is the ﬁt of the respective data points to the Schild equation (i.e. the slope of this line is unity). The intercept on the abscissa (where the log10
value of the dose-ratio e 1 equals zero) gives an equilibrium constant (KB) value for TCN 201 of 70 nM. Data from McKay et al. (2012) where the KB value for TCN 213 was
determined, is illustrated in grey for reference. The dotted line shows the ﬁt of all data points with a modiﬁed equation (see Material and methods; Christopoulos and Kenakin,
2002) that takes into account allosteric modulation of glycine binding by TCN 201. The ﬁt predicts an allosteric KB# value of 56 nM and an allosteric constant (a) of 0.0123. (f),
Schild plot for antagonism by TCN 201 of GluN1/GluN2A NMDARs but using D-serine, rather than glycine, as the GluN1-site agonist. Again the solid line is the ﬁt of the data to the
Schild equation and gives a KB value for TCN 201 in these experiments of 81 nM. The dotted line shows the ﬁt of all data points to the modiﬁed equation and predicts an allosteric KB#
value of 66 nM and an allosteric constant of 0.0106.
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shift in the dose ratio that can be obtained with TCN 201 is around
80-fold (¼ 1/a). However such a shift would only be achieved with
a TCN 201 concentration of approximately 275 mM which is well
above its limit of solubility. In addition we carried out Schild
analysis using D-serine, rather than glycine, as the GluN1-site
agonist (Fig. 3f). A linear regression ﬁt of the data points obtained
with 0.3, 1 and 3 mM TCN 201 gives a line with a slope of 0.87 (95%
conﬁdence interval: 0.71e1.03). The ﬁt of the data (solid line)
illustrated in Fig. 3e shows a line whose slope has been con-
strained to unity and gives a KB for TCN 201 of 81 nM e comparable
to the value obtained when glycine was used as the GluN1-site
agonist. Similar to our ﬁndings when glycine was used as the
GluN1-site agonist, the data point at the highest concentration of
TCN 201 (10 mM) gives an r value that deviates considerably from
the linearity. Again using the modiﬁed equation we estimated an
allosteric KB# of 66 nM and an allosteric constant of 0.0106. Given
the good agreement between these values with those obtained
when glycine was used as the GluN1-site agonist and data reported
in a recent study which has also examined the mechanism of action
of TCN 201 (Hansen et al., 2012) it would seem unlikely that the
deviation from linearity of the Schild plot arises from the limitation
of TCN 201’s solubility.3.4. Antagonism by TCN 201 of NMDAR-mediated responses in rat
cortical neurones
In a ﬁnal series of experiments we assessed the ability of TCN
201 to antagonize NMDAR-mediated currents in rat cortical neu-
rones to assess the utility of this compound in identifying NMDAR
subunit populations. It should be noted that as we used NMDA
(rather than glutamate) in these experiments we determined
whether TCN 201 (10 mM) blocked, to the same extent, GluN1/
GluN2A NMDAR-mediated currents elicited by NMDA/glycine
compared with currents elicited by glutamate/glycine. We
observed signiﬁcantly less inhibition of NMDA/glycine-evoked
currents (69.9  4.1%; n ¼ 12, p < 0.001, data not shown)
compared to glutamate/glycine-evoked currents (91.2  1.1%;
Fig. 2b). This emphasizes the importance of considering the nature
of the agonist used to evoke responses but establishes the
maximum inhibition expected for TCN 201 block of NMDA/glycine-
evoked currents for a population of NMDARs comprised solely of
GluN1 and GluN2A NMDAR subunits.
Fig. 4a shows a series of NMDAR-mediated currents recorded
from rat cortical neurones under three separate conditions. Fig. 4ai
shows a representative recording from a neurone (DIV 9e10) where
the predominantly expressed GluN2 subunit is anticipated to be
Fig. 4. Antagonism by TCN 201 of native NMDAR-mediated responses in rat cortical cultures. (a), left, example steady-state whole-cell currents activated by NMDA (50 mM) and
glycine (3 mM) recorded from cortical pyramidal cells voltage-clamped at 70 mV from (ai), DIV 9e10 neurones, (aii), DIV 9e10 neurones transfected with GluN2A NMDAR subunits,
and (aiii), DIV 15e18 neurones. To the right, traces illustrate the sensitivity of each of these NMDAR-mediated currents to the GluN2B-selective antagonist, ifenprodil (3 mM) and the
subsequent sensitivity of the ifenprodil-insensitive component of this current to TCN 201 (10 mM). (b), left, bar graph summarizing the mean percentage ifenprodil block of NMDAR-
mediated currents recorded from DIV 9e10 neurones (n ¼ 7), GluN2A-transfected DIV 9e10 neurones (n ¼ 6), and DIV 15e18 neurones (n ¼ 9). Right, mean percentage TCN 201
block (expressed as a percentage of the original current magnitude) of NMDAR-mediated currents recorded from neurones in each of the three categories illustrated in (a). (c), plot
illustrating the extent of ifenprodil and TCN 201 antagonism of NMDA-evoked currents from the same cell. Despite a wide range in the amount of block produced by either
ifenprodil or TCN 201 (particularly for recordings from GluN2A-transfected and from neurones in older cultures) the data show a strong (negative) correlation (R2 ¼ 0.91).
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Fig. 4b, ifenprodil (3 mM) produces substantial block (80  3%,
n ¼ 7) of this current e as would be anticipated for a NMDAR
population that contains a high proportion of GluN1/GluN2B
NMDARs. Importantly, TCN 201 gives only a modest block of this
current (5 2%) which is comparable to the extent of TCN 201 block
seen at recombinant GluN1/GluN2B NMDARs (Fig. 1c). To increase
the number of GluN2A-containing NMDARs we transfected neu-
rones with pCis-GluN2A plasmids (Rutter and Stephenson, 2000).
NMDAR-mediated currents recorded from these neurones
(Fig. 4aii) now displayed a reduced sensitivity to ifenprodil (24 3%
block, n ¼ 6; Fig. 4b) but increased sensitivity to TCN 201 (47  4%
block, n¼ 6; Fig. 4b). Finally, the developmental increase in GluN2A
expressionwas conﬁrmed by recording NMDAR-mediated currents
from neurones that had been cultured for longer time periods
(Fig. 4aiii). In these neurones we observed that currents were less
sensitive to ifenprodil (57  5% block, n ¼ 9; Fig. 4b) compared to
those from DIV 9e10 cultures. This reduction in ifenprodil sensi-
tivity was accompanied by an increase in the extent of the block
produced by TCN 201 compared to that observed for currents in DIV
9e10 (non-transfected) cultures (16  3% block, n ¼ 9; Fig. 4b,
p < 0.01). Furthermore, while the range of ifenprodil and TCN 201
block of currents showed considerable variation within each of
these groups there was a strong inverse correlation (R2 ¼ 0.91) in
the sensitivities of currents to these two NMDAR subtype-selective
antagonists (Fig. 4c). A similar observation has been documentedfor ifenprodil and TCN 213 block of NMDAR-mediated currents in
cortical neurones (McKay et al., 2012).
4. Discussion
Three main points in regard to antagonism of NMDARs by TCN
201 are made in this study. Firstly, TCN 201 is a selective GluN1/
GluN2A NMDAR antagonist showing little antagonism at GluN1/
GluN2B NMDARs. Secondly, TCN 201 acts in a non-competitive
manner with the extent of its block being dependent on the
concentration of the GluN1-site agonist (glycine or D-serine)
present in the external salt solution. Thirdly, TCN 201 antagonism
of NMDAR-mediated currents shows a negative correlation with
their ifenprodil sensitivity and therefore, in combination with
ifenprodil, can be used to monitor, pharmacologically, the expres-
sion levels of GluN2A and GluN2B NMDAR subunits in neuronal
populations.
4.1. GluN1-site agonist-dependency of TCN 201 antagonism
TCN 201 antagonism of GluN1/GluN2A NMDAR-mediated
currents is glycine (D-serine) dependent. In this respect TCN 201
antagonism resembles that produced by the chemically-related
compound TCN 213 (Bettini et al., 2010; McKay et al., 2012).
When compared with our recent study of TCN 213 antagonism of
NMDARs, the data presented here show that TCN 201 is a more
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(Bettini et al., 2010)). Furthermore, our data also suggest that TCN
201 is unable to block completely NMDAR-mediated responses
under conditions where the GluN1-site agonist is present at
concentrations that may reﬂect those found in cerebro-spinal ﬂuid
in vivo (Fig. 2b, d). The data obtained were ﬁtted with curves whose
minima were unconstrained predicted a maximal inhibition, in the
presence of saturating glycine (or D-serine), of around 40%. Due to
the limited solubility of TCN 201 in our solutions wewere unable to
verify the precise level of maximum inhibition experimentally but
the predicted incomplete block of NMDARs when glycine (or D-
serine) is present at30 mM needs to be borne in mind when using
this novel GluN2A-selective antagonist.
4.2. TCN 201 antagonism is not competitive
Quantitative analysis of antagonist action is best carried out
using Schild analysis (Arunlakshana and Schild, 1959) to determine
the nature of the antagonism and (if appropriate) the KB of the
antagonist. Our analysis reveals that TCN 201 does not act in
a competitive manner at GluN1/GluN2A NMDARs since the Schild
plots for TCN 201 when either glycine or D-serine was used as the
GluN1-site agonist deviated from linearity at the highest antagonist
concentration used in this study (10 mM). While we were able to ﬁt
a line with unity slope to the ﬁrst three data points of the TCN 201
Schild plots (Fig. 3e, f) the intercept on the abscissa perhaps more
properly describes the concentration of TCN 201 that gives a dose
ratio of 2 (the negative logarithm of which will equal the pA2 for
TCN 201) rather than strictly its KB value which should be reserved
for purely competitive antagonists (Wyllie and Chen, 2007).
Comparison of pA2 values for TCN 201 and TCN 213 (7.15 versus
5.69) shows that TCN 201 is approximately 30-timesmore potent at
GluN1/GluN2A NMDARs.
The hyperbolic nature of the TCN 201 Schild plot is indicative of
an allosteric non-competitive antagonism and the data points were
better ﬁtted by an alternative equation that has previously been
associated with the description of action of agonist-surmountable
non-competitive inhibitors acting at G-protein coupled receptors
(Christopoulos and Kenakin, 2002). In the case of these surmount-
able non-competitive inhibitors, deviations away from unity at
higher concentrations of antagonist are due to the saturable nature
of the antagonism. Since saturable behaviour can be achieved,
allosteric antagonists will shift the agonist concentration-response
curve to the right, in a manner similar to competitive antagonism,
but according to a deﬁned limit (Christopoulos and Kenakin, 2002).
Our estimates of an allosteric KB# of 56 nM (66 nM) and an allosteric
constant of 0.0123 (0.0106), when glycine (D-serine) is used as the
GluN1-site agonist, are in excellent agreement with a recent study
that has employed a similar analysis of TCN 201 antagonism at
recombinant NMDARs (Hansen et al., 2012). In their study, Hansen
et al. (2012) propose that TCN 201 binds to a site located at the
dimer interface between the GluN1 and GluN2 agonist binding
domains which leads to an acceleration of glycine (D-serine)
unbinding from the GluN1 subunit. The data we present here are
entirely consistent with such a mechanism of action.
Although the allosteric constant is close to zero for TCN 201
(when either glycine or D-serine is used as the GluN1-site agonist)
and therefore the Schild plot only begins to deviate from unity at
antagonist concentrations above about 3 mM this places a limit on
the maximum shift in the dose ratio that can be achieved of about
80e90-fold (¼1/a). Our previous study with TCN 213 (McKay et al.,
2012) generated a Schild plot with a unity slope suggesting
a competitive form of antagonism for this compound. It should,
however, be noted that relative to its KB (2 mM) the highest
antagonist concentration used (30 mM) would not have allowed usto observe a deviation from a unity slope if TCN 213 possesses
a similar allosteric constant to that of TCN 201.4.3. Utility of TCN 201 in identifying neuronal NMDAR subtypes
There are relatively few antagonists that block GluN2A-
containing NMDARs in a manner that allows them to be used to
identify unequivocally the subunit composition of native NMDARs
(Ogden and Traynelis, 2011). The KB values for NVP-AAM077
(Auberson et al., 2002) acting at GluN1/GluN2A and GluN1/
GluN2B NMDARs are only different by a factor of 5 (Frizelle et al.,
2006) therefore limiting the use of this antagonist. TCN 213
(Bettini et al., 2010) although possessing lower potency than NVP-
AAM077 at GluN1/GluN2A exhibits little activity at either
recombinant or native GluN2B-containing NMDARs (McKay et al.,
2012) allowing it to be used to distinguish, pharmacologically,
responses mediated by these two NMDAR subtypes. Our data
(Fig. 4) shows that TCN 201, like TCN 213, blocks NMDAR-mediated
currents in cortical neurones in a manner that is negatively corre-
lated with the extent of block produced by the GluN2B NMDAR
antagonist, ifenprodil (McKay et al., 2012). In primary cultures of
‘young’ neurones, TCN 201 produced little block of NMDA-evoked
currents consistent with the notion that such populations are
predominantly GluN2B-containing NMDARs (Carmignoto and
Vicini, 1992; Crair and Malenka, 1995; Flint et al., 1997; Hestrin,
1992; Sheng et al., 1994; Stocca and Vicini, 1998). Overexpression
of GluN2A NMDAR subunits in such cultures gave rise to responses
that showed increased sensitivity to TCN 201. Indeed in those cells
which showed the greatest block by TCN 201 (and least sensitivity
to ifenprodil) the extent of this block indicated that the ifenprodil-
insensitive current component was mediated by populations of
NMDARs mainly comprised of only GluN1 and GluN2A subunits
since the amount of block obtained was similar to that seen when
TCN 201 antagonized NMDA-evoked responses in oocytes
expressing GluN1/GluN2A NMDARs. Finally in older cultures the
extent of TCN 201 block was variable but always (negatively)
correlated with that of ifenprodil and indicated an increased
expression of GluN2A-containing NMDARs, as is to be expected
with this stage of development. What remains to be determined is
the relative contribution of heterodimeric (GluN1/GluN2A) and
heterotrimeric (GluN1/GluN2A/GluN2B) NMDAR combinations in
this population. Related to this is the fact that we do not know the
potency of TCN 201 when it acts at GluN2A/B-containing hetero-
trimeric NMDARs e a combination thought to represent
a substantial proportion of NMDARs in the adult forebrain (Chazot
and Stephenson, 1997; Rauner and Kohr, 2011).5. Conclusion
TCN201 is a potent selective inhibitorofGluN1/GluN2ANMDARs
that displays only minimal activity at GluN1/GluN2B NMDARs. The
potency of its antagonism is dependent on the concentration of the
GluN1-site agonist and not that of the GluN2-site agonist. Schild
analysis demonstrates that the nature of its antagonism is not
competitive but rather is consistent with the notion that TCN 201
acts by an allosteric non-competitive mechanism. TCN 201, like TCN
213 (McKay et al., 2012), can be used to monitor, pharmacologically,
the change in GluN2 NMDAR subunit expression levels in devel-
oping central neurones. Nevertheless, while TCN 201 offers the
opportunity to block selectively GluN2A-containing NMDARs care
mustbe taken inexperimental designs to takeaccountof (1) TCN201
block is strongly-dependent on the GluN1-site agonist concentra-
tion and (2) TCN 201 possesses a comparatively low solubility in salt
solutions that are commonly usedwhen assessingNMDAR function.
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